Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald D Perrone

Showing results (41-50 of 123) with videos related to

Pageof 13
Sort By:
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 5, 2011
Peripheral augmentation index and vascular inflammation in autosomal dominant polycystic kidney diseaseKevin S Heffernan, Jeffrey T Kuvin, Mark J Sarnak, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 6, 2017
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 TrialVicente E Torres, Arlene B Chapman, Olivier Devuyst, et al.
Scientific Reports|March 11, 2020
Implications of early diagnosis of autosomal dominant polycystic kidney disease: A post hoc analysis of the TEMPO 3:4 trialPeter Janssens, François Jouret, Bert Bammens, et al.
American Journal of Nephrology|February 7, 2017
Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney DiseaseVicente E Torres, Olivier Devuyst, Arlene B Chapman, et al.
Kidney International Reports|April 29, 2021
Per-Treatment <i>Post Hoc</i> Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKDAndrew J Mallett, Ronald D Perrone, Gopala Rangan, et al.
Kidney International|December 22, 2004
The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney diseaseTazeen H Jafar, Paul C Stark, Christopher H Schmid, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 8, 2014
Performance of creatinine-based GFR estimating equations in solid-organ transplant recipientsKamran Shaffi, Katrin Uhlig, Ronald D Perrone, et al.
Annals of Internal Medicine|July 16, 2003
National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratificationAndrew S Levey, Josef Coresh, Ethan Balk, et al.
Journal of the American Society of Nephrology : JASN|December 7, 2016
Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 TrialOlivier Devuyst, Arlene B Chapman, Ron T Gansevoort, et al.
Kidney Medicine|November 10, 2025
Qualitative Analysis and Comparison of Externally Led Patient-Focused Drug Development Concepts for Autosomal Recessive Polycystic Kidney Disease Against SONG InitiativesBelle Soyfer, Sorin Fedeles, Wendy Ruyle, et al.
Pageof 13

Showing results (41-50 of 123) with videos related to

Sort By:
Pageof 13
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 5, 2011
Peripheral augmentation index and vascular inflammation in autosomal dominant polycystic kidney diseaseKevin S Heffernan, Jeffrey T Kuvin, Mark J Sarnak, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 6, 2017
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 TrialVicente E Torres, Arlene B Chapman, Olivier Devuyst, et al.
Scientific Reports|March 11, 2020
Implications of early diagnosis of autosomal dominant polycystic kidney disease: A post hoc analysis of the TEMPO 3:4 trialPeter Janssens, François Jouret, Bert Bammens, et al.
American Journal of Nephrology|February 7, 2017
Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney DiseaseVicente E Torres, Olivier Devuyst, Arlene B Chapman, et al.
Kidney International Reports|April 29, 2021
Per-Treatment <i>Post Hoc</i> Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKDAndrew J Mallett, Ronald D Perrone, Gopala Rangan, et al.
Kidney International|December 22, 2004
The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney diseaseTazeen H Jafar, Paul C Stark, Christopher H Schmid, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 8, 2014
Performance of creatinine-based GFR estimating equations in solid-organ transplant recipientsKamran Shaffi, Katrin Uhlig, Ronald D Perrone, et al.
Annals of Internal Medicine|July 16, 2003
National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratificationAndrew S Levey, Josef Coresh, Ethan Balk, et al.
Journal of the American Society of Nephrology : JASN|December 7, 2016
Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 TrialOlivier Devuyst, Arlene B Chapman, Ron T Gansevoort, et al.
Kidney Medicine|November 10, 2025
Qualitative Analysis and Comparison of Externally Led Patient-Focused Drug Development Concepts for Autosomal Recessive Polycystic Kidney Disease Against SONG InitiativesBelle Soyfer, Sorin Fedeles, Wendy Ruyle, et al.
Pageof 13